Conceptual clarifications regarding Chilean Act 20850 on public funding of high-cost diseases
En 2015 se publica en Chile la Ley 20850, cuyo objetivo declarado es el financiamiento público de enfermedades raras y de aquellas de alto costo diagnóstico y terapéutico. Inserto en la ley hay un articulado a introducir en el Código Sanitario, que exige de las investigaciones clínicas que mantengan...
Main Author: | Miguel Hugo Kottow Lang |
---|---|
Format: | Article |
Language: | English |
Published: |
Medwave Estudios Limitada
2016-04-01
|
Series: | Medwave |
Subjects: |
Similar Items
-
Off-label prescription of drugs at hospital
by: Vicente Arocas Casañ, et al.
Published: (2016-03-01) -
The High “Cost” of Experimental Drugs Obtained Through Health Litigation in Brazil
by: Ricardo Eccard da Silva, et al.
Published: (2020-05-01) -
Impact of Repetitive Transcranial Magnetic Stimulation on Neurocognition and Oxidative Stress in Relapsing-Remitting Multiple Sclerosis: A Case Report
by: Eduardo Agüera, et al.
Published: (2020-08-01) -
Compassionate Use
by: Pranav Aurora
Published: (2015-05-01) -
The use of remdesivir outside of clinical trials during the COVID-19 pandemic
by: Vesa Halimi, et al.
Published: (2020-09-01)